Press Release

Frequency Therapeutics to Present Business and Pipeline Overview at the 38th Annual J.P. Morgan Healthcare Conference

January 7, 2020 at 9:00 AM EST

WOBURN, Mass.--(BUSINESS WIRE)--Jan. 7, 2020-- Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a Company overview at the 38th annual J.P. Morgan Healthcare conference.

Mr. Lucchino’s presentation will take place on Wednesday, January 15th at 11 a.m. PT (2 p.m. ET) in the Elizabethan A room at the Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session to be held in the Sussex room at 11:30 a.m. PT (2:30 p.m. ET). A live webcast of the both the presentation and the breakout session can be accessed on the investors section of the Frequency’s website,, or by linking here. A replay of the presentation will be posted on the Frequency website following the event.

About Frequency Therapeutics

Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Company’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The Company’s lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function. In a FX-322 Phase 1/2 study, statistically significant and clinically meaningful improvements in key measures of hearing function in patients with sensorineural hearing loss were observed. The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including a development program in multiple sclerosis.

Headquartered in Woburn, Mass., Frequency has a license and collaboration agreement with Astellas Pharma Inc. for FX-322, for which it retains U.S. rights, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including The Scripps Research Institute, Massachusetts Eye and Ear, Partners Healthcare and the Massachusetts Institute of Technology. For more information, visit and follow Frequency on Twitter @Frequencytx.

Source: Frequency Therapeutics

Investor Contact:
Carlo Tanzi, Ph.D.
Kendall Investor Relations

Media Contact:
Courtney Heath
Scient Public Relations